Mutation Spectrum of EGFR From 21,324 Chinese Patients With Non-Small Cell Lung Cancer (NSCLC) Successfully Tested by Multiple Methods in a CAP-Accredited Laboratory

被引:15
作者
Mao, Linlin [1 ]
Zhao, Weiwei [1 ]
Li, Xiaoxia [1 ]
Zhang, Shangfei [1 ]
Zhou, Changhong [1 ]
Zhou, Danyan [1 ]
Ou, Xiaohua [1 ,2 ]
Xu, Yanyan [1 ]
Tang, Yuanxiao [1 ]
Ou, Xiaoyong [1 ]
Hu, Changming [1 ]
Ding, Xiangdong [3 ]
Luo, Pifu [3 ]
Yu, Shihui [1 ,2 ]
机构
[1] KingMed Diagnost, Clin Genome Ctr, Guangzhou, Peoples R China
[2] Inst KingMed Translat Med, Guangzhou, Peoples R China
[3] KingMed Diagnost, Dept Pathol, Guangzhou, Peoples R China
关键词
non-small cell lung cancer; EGFR mutation testing; Sanger sequencing; real-time PCR; next-generation sequencing; STATISTICS;
D O I
10.3389/pore.2021.602726
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Genotyping epidermal growth factor receptor (EGFR) gene in patients with advanced non-small cell lung cancers (NSCLC) is essential for identifying those patients who may benefit from targeted therapies. Systemically evaluating EGFR mutation detection rates of different methods currently used in clinical setting will provide valuable information to clinicians and laboratory scientists who take care of NSCLC patients. This study retrospectively reviewed the EGFR data obtained in our laboratory in last 10 years. A total of 21,324 NSCLC cases successfully underwent EGFR genotyping for clinical therapeutic purpose, including 5,244 cases tested by Sanger sequencing, 13,329 cases tested by real-time PCR, and 2,751 tested by next-generation sequencing (NGS). The average EGFR mutation rate was 45.1%, with 40.3% identified by Sanger sequencing, 46.5% by real-time PCR and 47.5% by NGS. Of these cases with EGFR mutations identified, 93.3% of them harbored a single EGFR mutation (92.1% with 19del or L858R, and 7.9% with uncommon mutations) and 6.7% harbored complex EGFR mutations. Of the 72 distinct EGFR variants identified in this study, 15 of them (single or complex EGFR mutations) were newly identified in NSCLC. For these cases with EGFR mutations tested by NGS, 65.3% of them also carried tumor-related variants in some non-EGFR genes and about one third of them were considered candidates of targeted drugs. NGS method showed advantages over Sanger sequencing and real-time PCR not only by providing the highest mutation detection rate of EGFR but also by identifying actionable non-EGFR mutations with targeted drugs in clinical setting.
引用
收藏
页数:8
相关论文
共 27 条
[1]   Detection and Clinical Significance of Intratumoral EGFR Mutational Heterogeneity in Chinese Patients with Advanced Non-Small Cell Lung Cancer [J].
Bai, Hua ;
Wang, Zhijie ;
Wang, Yuyan ;
Zhuo, Minglei ;
Zhou, Qinghua ;
Duan, Jianchun ;
Yang, Lu ;
Wu, Meina ;
An, Tongtong ;
Zhao, Jun ;
Wang, Jie .
PLOS ONE, 2013, 8 (02)
[2]   Driven by by Mutations: The Predictive Value of Mutation Subtype in EGFR-Mutated Non-Small Cell Lung Cancer [J].
Castellanos, Emily ;
Feld, Emily ;
Horn, Leora .
JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (04) :612-623
[3]   Cancer Statistics in China, 2015 [J].
Chen, Wanqing ;
Zheng, Rongshou ;
Baade, Peter D. ;
Zhang, Siwei ;
Zeng, Hongmei ;
Bray, Freddie ;
Jemal, Ahmedin ;
Yu, Xue Qin ;
He, Jie .
CA-A CANCER JOURNAL FOR CLINICIANS, 2016, 66 (02) :115-132
[4]   Real-world EGFR testing in patients with stage IIIB/IV non-small-cell lung cancer in North China: A multicenter, non-interventional study [J].
Cheng, Ying ;
Wang, Yan ;
Zhao, Jun ;
Liu, Yunpeng ;
Gao, Hongjun ;
Ma, Kewei ;
Zhang, Shucai ;
Xin, Hua ;
Liu, Jiwei ;
Han, Chengbo ;
Zhu, Zhitu ;
Wang, Yan ;
Chen, Jun ;
Wen, Fugang ;
Li, Junling ;
Zhang, Jie ;
Zheng, Zhendong ;
Dai, Zhaoxia ;
Piao, Hongmei ;
Li, Xiaoling ;
Li, Yinyin ;
Zhong, Min ;
Ma, Rui ;
Zhuang, Yongzhi ;
Xu, Yuqing ;
Qu, Zhuohui ;
Yang, Haibo ;
Pan, Chunxia ;
Yang, Fan ;
Zhang, Daxin ;
Li, Bing .
THORACIC CANCER, 2018, 9 (11) :1461-1469
[5]   Mutation incidence and coincidence in non small-cell lung cancer: meta-analyses by ethnicity and histology (mutMap) [J].
Dearden, S. ;
Stevens, J. ;
Wu, Y. -L. ;
Blowers, D. .
ANNALS OF ONCOLOGY, 2013, 24 (09) :2371-2376
[6]  
Gridelli C, 2015, NAT REV DIS PRIMERS, V1, DOI [10.1038/nrdp.2015.9, 10.1038/nrdp.2015.48]
[7]  
Jemal A, 2011, CA-CANCER J CLIN, V61, P134, DOI [10.3322/caac.21492, 10.3322/caac.20115, 10.3322/caac.20107]
[8]   Molecular Testing Guideline for the Selection of Patients With Lung Cancer for Treatment With Targeted Tyrosine Kinase Inhibitors: American Society of Clinical Oncology Endorsement of the College of American Pathologists/International Association for the Study of Lung Cancer/Association for Molecular Pathology Clinical Practice Guideline Update [J].
Kalemkerian, Gregory P. ;
Narula, Navneet ;
Kennedy, Erin B. ;
Biermann, William A. ;
Donington, Jessica ;
Leighl, Natasha B. ;
Lew, Madelyn ;
Pantelas, James ;
Ramalingam, Suresh S. ;
Reck, Martin ;
Saqi, Anjali ;
Simoff, Michael ;
Singh, Navneet ;
Sundaram, Baskaran .
JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (09) :911-+
[9]   Molecular targeted therapy in the treatment of advanced stage non-small cell lung cancer (NSCLC) [J].
Kumarakulasinghe, Nesaretnam Barr ;
van Zanwijk, Nico ;
Soo, Ross A. .
RESPIROLOGY, 2015, 20 (03) :370-378
[10]   Prognostic and predictive effects of TP53 co-mutation in patients with EGFR-mutated non-small cell lung cancer (NSCLC) [J].
Labbe, Catherine ;
Cabanero, Michael ;
Korpanty, Grzegorz J. ;
Tomasini, Pascale ;
Doherty, Mark K. ;
Mascaux, Celine ;
Jao, Kevin ;
Pitcher, Bethany ;
Wang, Rick ;
Pintilie, Melania ;
Leighl, Natasha B. ;
Feld, Ronald ;
Liu, Geoffrey ;
Bradbury, Penelope Ann ;
Kamel-Reid, Suzanne ;
Tsao, Ming-Sound ;
Shepherd, Frances A. .
LUNG CANCER, 2017, 111 :23-29